Biotech Analyst Hsieh, along with Top Pick of 2024 Fusion Pharmaceuticals’ CEO Valliant and President & CBO Rawat, discuss Fusion’s clinical programs including lead asset FPI-2265 on a conference call to be held on December 7 at 1:30 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FUSN:
- Fusion Pharma participates in a conference call hosted by Cantor Fitzgerald
- Fusion expands pact with BWX Technologies to strengthen actinium supply
- BWX Technologies and Fusion Pharmaceuticals partner in actinium-225 production
- Fusion Pharmaceuticals reports Q3 EPS (25c), consensus (40c)
- Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
